

BIOCON GROUP

Q1 FY 2011 vs. Q1 FY 2010

FACT SHEET

BIOCON LIMITED (WITH AXICORP) - CONSOLIDATED & UNAUDITED**BALANCE SHEET***(Rs. Crores)*

Particulars	As at 30-Jun-10	As at 31-Mar-10
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	1,737	1,658
Total Shareholder's Funds	1,837	1,758
Minority interest	34	34
Deferred Tax Liability	51	51
Secured Loans	324	332
Unsecured Loans	120	182
Total Loan Funds	445	514
Total	2,366	2,356
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,282	1,244
Intangible Assets	253	170
Investments	431	431
Inventories	429	372
Sundry debtors	439	446
Cash and bank balances	85	140
Loans and advances	117	134
Total Current Assets, Loans & Advances	1,070	1,092
Less: Current liabilities and provisions	670	580
Net Current assets	400	512
Total	2,366	2,356

**BIOCON LIMITED (WITH AXICORP) - CONSOLIDATED & UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs Crores)

Particulars			
	Q1 FY11	Q1 FY10	Variance
<u>INCOME</u>			
Biopharmaceuticals	590	432	37%
Contract research	72	64	13%
Total Sales	662	496	34%
Other income	10	9	-
Total Income / Revenues	672	505	33%
<u>EXPENDITURE</u>			
Material & Power Costs	403	289	39%
Staff costs	70	53	32%
Research & Development (Net)	21	20	6%
Forex Loss/ (gain)	2	(3)	-
Other Expenses	35	35	0%
Manufacturing, staff & other exps	531	394	35%
PBDIT /EBIDTA	141	111	27%
Interest and finance charges	7	6	24%
PBDT	134	105	27%
Depreciation	38	32	16%
PBT	96	73	32%
Taxes	16	14	20%
PROFIT FOR THE PERIOD	80	59	35%
Add/(less): Minority interest / Share of Losses in Associates	(3)	(1)	-
NET PROFIT (PAT)	77	58	33%
EPS on issued capital Rs.	3.84	2.90	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers.

Biopharmaceuticals includes licensing income of Rs 21 crores in Q1 FY2011 vs. Rs 2 crores in Q1 FY 2010.

Gross Research and Development spend for Q1 FY2011 was Rs 32.5 crores.